
    
      This is a prospective clinical study of ex-vivo selected, engineered, and expanded PD-1
      knockout T cells from autologous origin. 16 advanced esophageal cancer patients are planned
      to receive two cycles of PD-1 knockout engineered T cells infusion. Immunological markers are
      analyzed as well.
    
  